Article · 5 Oct 2026
Conference abstract
PEG-Modified biosimilars: Potential role in the emerging global biosimilar market
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The newly amended Public Health Service (PHS) Act clears the way for an abbreviated licensure pathway to ?Biosimilars? or to ?Interchangeable? with an FDA approved biological product. Now it is only a matter of time biosimilars hit the US, Japan and other world markets, if it isn?t already. EU has several Biosimilars presently in the market. However, Biosimilars suffer the same clinical shortcomings as that of the original ?innovator? molecules, such as short circulating half-life, immunogenicity and proteolytic degradation, among others.This is especially true for cytokines, hormones, growth factors and antibody fragments. These shortcomings could be circumvented by the application of the well-established and proven PEGylation technology to biosimilars. In this presentation, the rationale, and clinical development strategies including reasonable timelines are presented. In order to be attractive to the medical community and to be competitive in the market place, PEG-biosimilars must be safe, more potent, longer-acting and cost-effective compared to their corresponding innovator biomolecules.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Pascal Bailon”